The Kirby Institute (formerly the National Centre in HIV Epidemiology and Clinical Research), University of New South Wales, Sydney, Australia.
Sex Transm Dis. 2012 Feb;39(2):136-46. doi: 10.1097/OLQ.0b013e31823ed4ec.
Repeat infection with Chlamydia trachomatis following treatment is common and increases the risk of sequelae. Despite clinical guidelines recommending rescreening within 3 months of treatment, rescreening rates remain low. We undertook a systematic review to identify studies that compared rates of rescreening for repeat chlamydial infection between patients receiving and not receiving an intervention.
We searched Medline, EMBASE, and conference Web sites from 2000 to September 2010 using variations of the terms "chlamydia" and "rescreening" and "intervention." We used meta-analysis to calculate the overall relative risk (RR) effect on rescreening rates by study design and strategy type.
We identified 8 randomized controlled trials (RCTs) and 4 controlled observational studies, all conducted in the United States. Four RCTs assessed mailed screening kits ± reminders, with an average effect estimate of 1.30 (95% confidence interval [CI]: 1.01-1.50); 2 RCTs assessed motivational interviewing ± reminders with a summary effect of 2.15 (95% CI: 0.92-3.37); one RCT evaluated the effect of reminders with a RR of 9.67 (95% CI: 1.31-71.31), and another RCT assessed the effect of a $20 patient incentive with a RR of 1.16 (95% CI: 0.62-2.17). Three controlled observational studies assessed reminder strategies with RRs of 1.97 (95% CI: 1.76-2.21), 1.01 (95% CI: 0.66-1.55), and 1.88 (95% CI: 1.58-2.24)-a summary effect was not calculated due to significant heterogeneity; and one controlled observational study assessed the promotion of clinical guidelines with a RR of 1.35 (95% CI: 0.96-1.90).
The review suggests that the use of mailed screening kits is an important strategy to increase rescreening, reminder systems are promising, and motivational interviewing is worth investigation.
沙眼衣原体感染经治疗后再次感染较为常见,且会增加发生后遗症的风险。尽管临床指南建议在治疗后 3 个月内进行重新筛查,但重新筛查的比例仍然较低。我们进行了一项系统评价,以确定比较接受和不接受干预的患者中重复衣原体感染重新筛查率的研究。
我们检索了 2000 年至 2010 年 9 月间 Medline、EMBASE 和会议网站上的医学文献,使用了“沙眼衣原体”和“重新筛查”及“干预”的变体。我们使用荟萃分析根据研究设计和策略类型计算重新筛查率的总体相对风险(RR)效应。
我们共确定了 8 项随机对照试验(RCT)和 4 项对照观察性研究,这些研究均在美国进行。4 项 RCT 评估了邮寄筛查工具包+提醒,平均效果估计值为 1.30(95%置信区间[CI]:1.01-1.50);2 项 RCT 评估了动机性访谈+提醒,综合效果为 2.15(95%CI:0.92-3.37);一项 RCT 评估了提醒的效果,RR 为 9.67(95%CI:1.31-71.31),另一项 RCT 评估了 20 美元患者激励的效果,RR 为 1.16(95%CI:0.62-2.17)。3 项对照观察性研究评估了提醒策略,RR 分别为 1.97(95%CI:1.76-2.21)、1.01(95%CI:0.66-1.55)和 1.88(95%CI:1.58-2.24)-由于存在显著的异质性,因此未计算综合效果;一项对照观察性研究评估了推广临床指南的效果,RR 为 1.35(95%CI:0.96-1.90)。
综述表明,邮寄筛查工具包是提高重新筛查率的重要策略,提醒系统很有前途,动机性访谈值得进一步研究。